Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma

Oncology Reports

Volumn 8, Issue 1, 2001, Pages 157-160

  Nelkin, Barry D ^a   Ball, D W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Antivascular therapy; Cancer chemotherapy; Neuroendocrine cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; COMBRETASTATIN A 4; COMBRETASTATIN A-4; DOXORUBICIN; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DRUG EFFECT; DRUG SCREENING; FEMALE; HEART; HEART MUSCLE; HUMAN; MEDULLARY CARCINOMA; MOUSE; NUDE MOUSE; ORGAN SIZE; PATHOLOGY; THYROID TUMOR; TRANSPLANTATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, MEDULLARY; CELL DIVISION; DOXORUBICIN; FEMALE; HEART; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MYOCARDIUM; NEOPLASM TRANSPLANTATION; ORGAN SIZE; STILBENES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035233996     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.8.1.157     Document Type: Article

References (2)

1. Behr TM, Wulst E, Radetzdy S, Blumenthal RD, Dunn RM, Gratz S, Raue-Fränk M, Schmidbcrger H, Rauc F and Becker W: Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 57: 5309-5319, 1997.
2. Fontanini G, Vignati S, Pacini F, Pollina L and Basolo F: Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol 9: 636-641, 1996.